Skip to main content

Table 3 Outcome in total group and according to SHARF severity classes

From: Renal replacement therapy is an independent risk factor for mortality in critically ill patients with acute kidney injury

  Overall SHARF score P-value of difference
   <30 30-60 >60  
Number of AKI patients n = 1303 n = 202 n = 341 n = 688  
Hospital mortality 50.3% 21.8% 40.5% 63.7% <0.001
ICU and hospital stay      
   Days in ICU: mean (SD) 14.1 (16.4) 7.9 (10.0) 13.8 (16.2) 16.0 (17.4) <0.001
   Days in hospital: mean (SD) 34.2 (36.6) 29.0 (30.8) 38.8 (43.4) 33.4 (33.7) 0.009
Renal outcome in survivors      
   CKD stage 1-2 (eGFR > = 60 ml/minute) 38.6% 30.7% 41.4% 43.2%  
   CKD stage 3 (eGFR 30-59 ml/minute) 35.0% 34.3% 30.8% 39.2%  
   CKD stage 4 (eGFR 15-29 ml/minute) 10.7% 12.4% 13.0% 7.0%  
   CKD stage 5 (eGFR <15 ml/minute or ESKD) 15.7% 22.6% 14.8% 10.6% 0.009
  1. AKI, acute kidney injury; CKD, chronic kidney disease; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; SHARF score, Stuivenberg Hospital Acute Renal Failure score [19]